SOCMA Voices Concern over IST Provisions in Chemical-Site Security Measures - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SOCMA Voices Concern over IST Provisions in Chemical-Site Security Measures


ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society of Chemical Manufacturers and Affiliates (SOCMA) criticized the Secure Chemicals Facilities Act, which would require chemical facilities to use inherently safer technology (IST) as part of chemical-site security measures. The bill, which is cosponsored by Sen. Frank Lautenberg (D–NJ), was recently reintroduced as Congress considers whether to extend the Chemical Facility Anti-Terrorism Standards (CFAT), )which include current federal chemical-site security provisions.

CFATS are risk-based performance standards designed to ensure the security of US chemical facilities. They require covered chemical facilities to prepare security vulnerability assessments and to develop and implement site-security plans, which include measures that satisfy the identified risk-based performance standards. Although SOCMA supports CFATS, it opposes the use of IST in those provisions. IST is a conceptual framework that covers chemical-processing procedures, equipment, protection, and when feasible, the use of safer substances.

“While four previous bills have been introduced this Congress extending the current security rules, Lautenberg has chosen to advocate for costly and unnecessary adjustments to standards that are widely believed to be comprehensive and accountable,” said Bill Allmond, SOCMA’s vice-president of government relations, in an Apr. 1, 2011 SOCMA press release. In testimony before the House Energy and Commerce Committee's Subcommittee on Environment and the Economy, on Mar. 31, 2011, Allmond said that  “[IST] is an elegant concept, but the reality is almost never that simple. A reduction in hazard will reduce overall risk if, and only if, that hazard is not displaced to another time or location, or results in the creation of some new hazard.” He noted that no agreed-upon methodology exists to measure whether one process is inherently safer than another process. “For all these reasons, the world’s foremost experts in IST and chemical engineering have consistently recommended against regulating inherent safety for security purposes,” he said.

SOCMA supports other legislation (HR 908) that would extend the current authority of CFATS to the Department of Homeland Security CFATS through 2017. “The need for annual reauthorization of the program has created uncertainty for facilities regulated by CFATS,” said Allmond in his written testimony. “Without the assurance of a long-term authorization of these regulations, companies run a risk of investing in costly activities today that might not satisfy regulatory standards tomorrow.”

SOCMA will continue to work with the House and Senate towards the passage of a long-term authorization of CFATS.  On Apr. 13,2011, SOCMA members willy take their message directly to Congress and discuss their position with lawmakers and their staff during SOCMA Connect’s Fourth Annual Washington Fly-in.

See related stories:
SOCMA Urges Congressional Action on Chemical-Site Security Standards (ePT)

SOCMA Voices Concern over Chemical-Site Security Bill (ePT)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here